Testing a new drug with clot removal for severe back-of-the-brain stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You had a sudden blockage of the main artery in the back part of your brain (basilar artery)
- Your stroke is severe enough that you have a score of 10 or higher on the NIH stroke scale
- You are able to start the clot-removal procedure within 24 hours of the first symptoms
- You do not have a bleeding disorder, active infection, or known allergies to the study drug or contrast dye
- You are not pregnant or planning pregnancy in the next 90 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug that lowers inflammation can reduce the risk of another stroke in people with narrowing of a brain artery. The treatment is given after a mild stroke or mini-stroke.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
This study tests whether a medication called a GLP-1 receptor agonist (a type of drug used for diabetes) can improve recovery after a major stroke that was treated with a procedure to remove the blood clot. The goal is to see if this drug helps reduce further brain damage and improve outcomes.
This trial studies whether giving an anti-inflammatory drug called tocilizumab after emergency clot removal improves recovery from a severe stroke caused by a blocked artery in the brain.
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.